Acar, CanerSahin, GokhanYuksel, Haydar CagatayKaraca, Burcak2024-08-312024-08-3120241120-009X1973-9478https://doi.org/10.1080/1120009X.2024.2349858https://hdl.handle.net/11454/105451Pembrolizumab is an immune checkpoint inhibitor that acts via PD-1 blockade. Recent studies have shown its effectiveness in treating various solid organ tumours. However, unlike cytotoxic chemotherapeutic agents, pembrolizumab may cause immune-related adverse effects. These immune-related adverse effects are generally mild, although patients who experience grade-three or higher side effects may require hospitalisation. In particular, cardiopulmonary side effects are associated with high mortality rates. We report the case of a 24-year-old female patient with alveolar soft part sarcoma accompanied by rare and difficult-to-treat pulmonary hypertension induced by pembrolizumab.en10.1080/1120009X.2024.2349858info:eu-repo/semantics/closedAccessImmunotherapyAdverse Drug ReactionImmune-Related Adverse EventsPulmonary Arterial HypertensionArticleWOS:0012190313000012-s2.0-8519252726638717744Q3N/A